The EMD AML approval pathway is where we have already sunk costs for FDA advisors and the FDA strategy meeting regarding an IND. So even with partnership talks we reserve the right to go it alone, at least helpful in negotiations if not reality
The EMD AML approval pathway is where we have already sunk costs...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.75 |
Change
-0.040(2.23%) |
Mkt cap ! $297.9M | |||
| Open | High | Low | Value | Volume |
| $1.79 | $1.79 | $1.72 | $146.2K | 83.61K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2901 | $1.73 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.75 | 994 | 1 |
View Market Depth
| Last trade - 16.10pm 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.74 |
Change
-0.040 ( 1.51 %) |
||||
| Open | High | Low | Volume | ||
| $1.76 | $1.77 | $1.72 | 23546 | ||
| Last updated 15.56pm 17/06/2024 ? | |||||
| RAC (ASX) Chart |
